Biogen boosts its outlook after a blockbuster quarter

Biogen boosts its outlook after a blockbuster quarter


Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy drug, Spinraza, which is priced at $750,000 for the first year of therapy. Buoyed by the demand for Spinraza, the U.S. drugmaker raised its full-year earnings and revenue forecasts, sending shares up 4.1 percent in premarket trading.



from Biotech News